









# PIPELINE

## Candidate: Lasofoxifene – Oral SERM

In Planning  
Enrollment Complete  
Potentially Registrational

	Preclinical	Phase 1	Phase 2	Phase 3/4	
<div style="display: flex; align-items: center;"> <div style="border: 1px solid white; padding: 2px; margin-right: 10px;">                     Monotherapy • Combination Therapy ••                 </div> </div>					
<b>► Breast Cancer</b>					
•	ELAINE 1: Lasofoxifene vs. Fulvestrant 				<input type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>
••	ELAINE 2: Laso + Abemaciclib 				<input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> 
•	ELAINE 3: Lasofoxifene vs. Fulvestrant 				<input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>
••	ELAINE 4: Laso + CDK 4/6 Inhibitor 				<input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>
••	Laso + mTOR Inhibitor				<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 
••	Laso + AKT Inhibitor				<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
<b>► Treatment Resistant Tumors (non-ESR1<sup>mut</sup>) and ESR1<sup>mut</sup></b>					
•	Laso vs. Fulv				
••	Laso + Palbo vs. Fulv + Palbo				
<b>► Gynecological Cancer</b>					
•/••	Lasofoxifene – Endometrial Cancer				
<b>► ESR1 Assay</b>					
	Research Assay		Clinical Trial Assay (CTA)	CTA/CDx	